FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | | | | |
|-------------------|-----------|--|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | | |
| Estimated average | burden | | | | | | | | | |

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

| | | | | | 1 | | 0(11) 0 | 1 1110 1 | | 00 | прапу Аст С | 71 10 10 | | | | | | | |
|--|--|-----------|----------|---|--|--|--------------------------------------|----------|--|---|--|---|--|--|---------------|----------------------------|--|--|---|
| Name and Address of Reporting Person* Leaching Devid I. | | | | 2. Issuer Name and Ticker or Trading Symbol Frequency Therapeutics, Inc. [FREQ] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | | |
| <u>Lucchino David L.</u> | | | | Ziegeneg increpentes, mei [TREQ] | | | | | | | | X Dire | | tor | | 10% O | wner | | |
| (Last) | (F | First) (I | Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) | | | | | | | X | Office below | er (give title v) | | Other (: below) | specify | | |
| C/O FREQUENCY THERAPEUTICS, INC. | | | | 07/25/2023 | | | | | | | | | President and CEO | | | | | | |
| 75 HAYDEN AVE, SUITE 300 | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | | | | |
| (Street) | | | | | | | | | | | X | Form filed by One Reporting Person | | | | son | | | |
| LEXINGTON MA 02421 | | | | | | | | | | | | Form filed by More than One Reporting Person | | | | orting | | | |
| (City) | (5 | State) (2 | Zip) | | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | | |
| | | | | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | |
| | | Table | I - No | n-Deriva | tive S | ecui | ities | Acc | uired, | Dis | posed of | , or E | 3enef | iciall | y Owr | ned | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/ | | | | Execution Date, | | , | Transaction Disposed Code (Instr. 5) | | | ies Acquired (A) Of (D) (Instr. 3, 4 | | 4 and Secur Benef Owner Follow | | icially d ving | Form (D) o | n: Direct or ect (I) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | | | Code | v | Amount | (A) or (D) | | ce | Reported Transaction(s) (Instr. 3 and 4) | | | | | |
| Common Stock 07/25/20 | | | | | 023 | | | S | | | 2,803(1) | 1) D S | | 0.5 ⁽²⁾ | 686,130 | | | D | |
| Common Stock 07/26/20 | | | | .023 | | | | S | | 2,609(1) | D | \$0 | .52 ⁽³⁾ | 683,521 | | | D | | |
| | | Tak | ole II - | - Derivativ | | | | | | | | | | | Owne | ed | | | |
| | | | | (e.g., pu | ts, cai | IS, V | varra | ınts, | option | 15, (| convertib | ie se | curiti | es) | | | | | 1 |
| 1. Title of Derivative Security (Instr. 3) | vative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any | | | ution Date, | 4. Transaction Code (Instr. 8) | | Number I | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and | | 8. Price of Derivative Security (Instr. 5) | | | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exercisable | | Expiration Date | Title | Amount or Number of Shares | er | | | | | |

Explanation of Responses:

- 1. Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$0.491 to \$0.512. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- 3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$0.511 to \$0.546. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

/s/ James P. Abely, Attorneyin-Fact for David L. Lucchino 07/27/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.